TY - JOUR AU - Nakamura, Tatsufumi AU - Matsuo, Tomohiro AU - Fukuda, Taku AU - Yamato, Shinji AU - Yamaguchi, Kentaro AU - Kinoshita, Ikuo AU - Matsuzaki, Toshio AU - Nishiura, Yoshihiro AU - Nagasato, Kunihiko AU - Narita-Masuda, Tomoko AU - Nakamura, Hideki AU - Satoh, Katsuya AU - Sasaki, Hitoshi AU - Sakai, Hideki AU - Kawakami, Atsushi PY - 2013 DA - 2013/08/15 TI - Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial JO - BMC Medicine SP - 182 VL - 11 IS - 1 AB - Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic myelopathy characterized by motor dysfunction of the lower extremities and urinary disturbance. Immunomodulatory treatments are the main strategy for HAM/TSP, but several issues are associated with long-term treatment. We conducted a clinical trial with prosultiamine (which has apoptotic activity against HTLV-I-infected cells) as a novel therapy in HAM/TSP patients. SN - 1741-7015 UR - https://doi.org/10.1186/1741-7015-11-182 DO - 10.1186/1741-7015-11-182 ID - Nakamura2013 ER -